Question normal

As we all know, although endocrine therapy is effective to decrease the risk of recurrence for ER+ breast cancer patients, this therapies bring inevitable adverse events, e.g. increasing risk of developing endometrial cancer. To bring the personalized strategy for this group of patients a step forward, could we avoid prescribing endocrine therapy for a group early stage patients without increasing the risk of recurrence and contralateral cancer?